Protagonist Therapeutics Participates in a Conference Call With JPMorgan
TD Cowen Initiates Protagonist Therapeutics(PTGX.US) With Buy Rating, Announces Target Price $65
Express News | Protagonist Therapeutics Inc : TD Cowen Initiates Coverage With Buy Rating; Target Price $65
The 8.6% Return This Week Takes Protagonist Therapeutics' (NASDAQ:PTGX) Shareholders Five-year Gains to 231%
H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $50
Analysts Offer Insights on Healthcare Companies: Walgreens Boots Alliance (WBA), Belite Bio, Inc. ADR (BLTE) and Protagonist Therapeutics (PTGX)
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
Truist Financial Initiates Protagonist Therapeutics(PTGX.US) With Buy Rating, Announces Target Price $60
Truist Initiates Protagonist Therapeutics at Buy With $60 Price Target
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
Protagonist Therapeutics Is Maintained at Market Outperform by JMP Securities
Protagonist Therapeutics Price Target Cut to $43.00/Share From $45.00 by JMP Securities
Express News | HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $40
Protagonist Therapeutics Analyst Ratings
Express News | Protagonist Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $40 From $38
JMP Securities Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $43
Capital One Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $48
JMP Securities Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Cuts Target Price to $43
Buy Rating Affirmed for Protagonist Therapeutics on Strong Pipeline and Strategic Partnerships
Protagonist Therapeutics | 10-Q: Q2 2024 Earnings Report